Voyageur Pharmaceuticals Ltd
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Brent Willis
- Full Time Employees
- 49
- Sector
- Process industries
- Industry
- Chemicals: agricultural
- Address
- 4103 Centre Street NW Calgary AB Canada T2E 2Y6
- IPO Date
- May 18, 2012
- Website
- voyageurminerals.ca
- Similar Companies
- Business
- Voyageur Pharmaceuticals Ltd. (VM.V) develops and manufactures natural-mineral-based active pharmaceutical ingredients (APIs), specializing in barium sulfate and iodine-based contrast agents for diagnostic imaging in CT, fluoroscopy, MRI, and ultrasound procedures. The company offers a portfolio of Health Canada-approved barium contrast products, including Smooth HD and Smooth LD (high- and low-density fluoroscopy suspensions), Smooth X (oral CT contrast), Vision HD and Vision LD (high- and low-density powders), and V-Gas (effervescent GI distension agent in development); it also pursues iodine and endohedral fullerene-based innovations for enhanced imaging solutions. Founded in 2017 and headquartered in Calgary, Alberta, Canada, Voyageur operates mineral exploration and development assets in British Columbia, Canada, and Utah, USA, with a vertically integrated supply chain from raw barite mining to finished pharmaceuticals targeting radiology clinics and hospitals primarily in North America. In December 2024, the company signed a letter of intent with a multinational pharmaceutical firm to optimize contrast media production and expand market access, aiming for a definitive agreement in early 2025; it also formed a March 2024 alliance with Applied Pharmaceutical Innovations for carbon-based imaging drugs and initiated commercial shipments of barium products to Canadian clinics in August 2025. Voyageur, formerly Voyageur Minerals Ltd. until its December 2019 name change, continues advancing FDA approvals, global distribution contracts, and new fullerene drug programs to secure North American supply independence.
Company News
Voyageur Pharmaceuticals Announces Completion of Shares for Debt Settlement
Voyageur Pharmaceuticals Announces Proposed Issuance of Shares for Debt
Voyageur Pharmaceuticals Achieves First Milestone on Feasibility Study for Iodine Production; Secures USD $1 Million Payment
Voyageur Pharmaceuticals Advances Mueller Iodine Extraction Process with 99.8% Purity Results and Planned Field Pilot Testing
Voyageur Pharmaceuticals Announces the Engagement of Red Cloud Securities as Market Maker
Voyageur Pharmaceuticals Engages Fluor to Advance Feasibility Studies for Iodine Production and Integrated Contrast Drug Manufacturing Facility
Voyageur Pharmaceuticals Evaluating Three Locations in the United States for Integrated Iodine and Barium Contrast Media Manufacturing Facility, a Multi-Phase Investment Expected to Generate Significant Economic Impact and High-Skilled Jobs; Competitive Site Selection Process Underway
Voyageur Pharmaceuticals Ltd. Submits Multi-Year Area-Based Exploration Permit Application for Bulk Sampling and Feasibility Support at Frances Creek Barite Project
Voyageur Announces Closing Of Non-Brokered Private Placement Pursuant To Listed Issuer Financing Exemption
Voyageur Announces Update To Non-Brokered Life Offering
Voyageur Pharmaceuticals Confirms Pharmaceutical-Grade Purity of Barite from Frances Creek and Progresses to Health Canada Human Trial with Alberta Innovates Grant; Announces Stock Option and DSU grants, and Proposed Issuance of Securities for Debt
Voyageur Pharmaceuticals Announces Collaboration with Bayer
Voyageur Pharmaceuticals Strengthens Scientific Team by Adding Dr. Brian Mueller as Director of Chemistry and Secures Exclusive Ownership of Iodine Extraction Technology
Voyageur Pharmaceuticals Ltd. Strengthens Board of Directors with Seasoned Financial Executive Virginia Alling to Drive U.S. Market Expansion
Voyageur Pharmaceuticals Signs Non-Exclusive Distribution & Wholesale Agreement with PHALANX
Voyageur Pharmaceuticals Ltd. Strengthens Board of Directors with Wall Street Expertise to Facilitate U.S. Market Expansion
Voyageur Pharmaceuticals Launches U.S. Iodine Feasibility Study to Establish First Fully Integrated North American Contrast Drug Manufacturing Platform
Voyageur Pharmaceuticals Initiates First Commercial Shipments of Barium Contrast Products to Canadian Clinics
Voyageur Pharmaceuticals Announces Exercise of Warrants for Gross Proceeds of $1.69 Million
Voyageur Pharmaceuticals partners with VAST on Frances Creek permitting work